Avantax Planning Partners, Inc. Vir Biotechnology, Inc. Transaction History
Avantax Planning Partners, Inc.
- $2.78 Billion
- Q3 2024
A detailed history of Avantax Planning Partners, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Avantax Planning Partners, Inc. holds 51,359 shares of VIR stock, worth $519,239. This represents 0.01% of its overall portfolio holdings.
Number of Shares
51,359
Previous 51,359
-0.0%
Holding current value
$519,239
Previous $457,000
15.97%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VIR
# of Institutions
214Shares Held
86.6MCall Options Held
127KPut Options Held
1.19M-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$169 Million1.03% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$166 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$133 Million0.0% of portfolio
-
State Street Corp Boston, MA5.63MShares$56.9 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.57MShares$36.1 Million0.63% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $1.34B
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...